Literature DB >> 21270511

Growth hormone treatment in adults with growth hormone deficiency: the transition.

M E Molitch1.   

Abstract

The approval of GH treatment of adults with GH deficiency (GHD) raises issues regarding continuation of GH treatment in the GH-deficient child following achievement of near adult height. The transition period begins in late puberty and ends with full adult maturation and includes hormonal and many lifestyle changes. Children treated with GH should be retested near the time of reaching adult height to determine if they have persistence of GHD. Although most children with organic causes of GHD will again be found to have GHD on retesting, most of those with idiopathic GHD will not. Retesting usually involves measurement of IGF-I and stimulation with insulin-induced hypoglycemia or arginine-GHRH, but important questions remain about adjustment of established cut-offs for age and body mass index. Most studies have shown the benefit of GH treatment in young adults with GHD in body composition, especially the achievement of peak bone mass. It is important for pediatric endocrinologists to discuss the potential need for continued treatment beyond achievement of adult height at the time of initiation of GH treatment, especially in those children with organic causes of GHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270511     DOI: 10.1007/BF03347046

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  73 in total

Review 1.  Molecular basis of combined pituitary hormone deficiencies.

Authors:  Laurie E Cohen; Sally Radovick
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

2.  Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests.

Authors:  Xiao-Dan Qu; Irene T Gaw Gonzalo; Mohammed Y Al Sayed; Pejman Cohan; Peter D Christenson; Ronald S Swerdloff; Daniel F Kelly; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency.

Authors:  Kyriaki S Alatzoglou; James P Turton; Daniel Kelberman; Peter E Clayton; Ameeta Mehta; Charles Buchanan; Simon Aylwin; Elisabeth C Crowne; Henrik T Christesen; Niels T Hertel; Peter J Trainer; Martin O Savage; Jamal Raza; Kausik Banerjee; Sunil K Sinha; Svetlana Ten; Talat Mushtaq; Raja Brauner; Timothy D Cheetham; Peter C Hindmarsh; Primus E Mullis; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

4.  Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.

Authors:  B M Biller; G Sesmilo; H B Baum; D Hayden; D Schoenfeld; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment.

Authors:  M Tauber; P Moulin; C Pienkowski; B Jouret; P Rochiccioli
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

6.  Factors influencing the desire for long-term growth hormone replacement in adults.

Authors:  S J Holmes; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  1995-08       Impact factor: 3.478

Review 7.  Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency.

Authors:  Giampiero I Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  J Pediatr Endocrinol Metab       Date:  2003-03       Impact factor: 1.634

8.  Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.

Authors:  G S Conway; M Szarras-Czapnik; K Racz; A Keller; P Chanson; M Tauber; M Zacharin
Journal:  Eur J Endocrinol       Date:  2009-03-26       Impact factor: 6.664

9.  Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency.

Authors:  H B Baum; L Katznelson; J C Sherman; B M Biller; D L Hayden; D A Schoenfeld; K E Cannistraro; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

10.  Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor.

Authors:  Berrin Ergun-Longmire; Ann C Mertens; Pauline Mitby; Jing Qin; Glenn Heller; Weiji Shi; Yutaka Yasui; Leslie L Robison; Charles A Sklar
Journal:  J Clin Endocrinol Metab       Date:  2006-07-05       Impact factor: 6.134

View more
  6 in total

Review 1.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

2.  Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement.

Authors:  S Cannavò; M Cappa; D Ferone; A M Isidori; S Loche; M Salerno; M Maghnie
Journal:  J Endocrinol Invest       Date:  2022-08-12       Impact factor: 5.467

3.  The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®).

Authors:  Charlotte Höybye; Lars Sävendahl; Henrik Thybo Christesen; Peter Lee; Birgitte Tønnes Pedersen; Michael Schlumpf; John Germak; Judith Ross
Journal:  Clin Epidemiol       Date:  2013-04-26       Impact factor: 4.790

Review 4.  Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective.

Authors:  M Ahmid; S F Ahmed; M G Shaikh
Journal:  Ther Clin Risk Manag       Date:  2018-11-23       Impact factor: 2.423

5.  Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.

Authors:  Stephany H Donze; Layla Damen; Janiëlle A E M van Alfen-van der Velden; Gianni Bocca; Martijn J J Finken; Gera J G Hoorweg-Nijman; Petr E Jira; Mariëtte van Leeuwen; Anita C S Hokken-Koelega
Journal:  Clin Endocrinol (Oxf)       Date:  2019-04-30       Impact factor: 3.478

6.  Multi-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiency.

Authors:  G Johannsson; K Nespithal; U Plöckinger; V Alam; M McLean
Journal:  J Endocrinol Invest       Date:  2018-02-27       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.